Status:
COMPLETED
MONO: Symbicort® Single Inhaler Therapy and Conventional Best Standard Treatment for the Treatment of Persistent Asthma in Adolescents and Adults
Lead Sponsor:
AstraZeneca
Conditions:
Asthma
Eligibility:
All Genders
12+ years
Phase:
PHASE4
Brief Summary
The purpose of the study is to compare the efficacy of a flexible dose of Symbicort (budesonide/formoterol) with conventional stepwise best standard treatment in patients with persistent asthma.
Eligibility Criteria
Inclusion
- Diagnosis of asthma \>= 3 months
- Prescribed daily use of glucocorticosteroids for at least 3 months prior to Visit 1
Exclusion
- Smoking history \> 10 pack-years
- Asthma exacerbation requiring change in asthma treatment during the last 14 days prior to inclusion
- Any significant disease or disorder that may jeopardize the safety of the patient.
- Additional inclusion and exclusion criteria will be evaluated by the investigator.
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
End Date :
October 1 2006
Estimated Enrollment :
1900 Patients enrolled
Trial Details
Trial ID
NCT00242411
Start Date
September 1 2004
End Date
October 1 2006
Last Update
January 24 2011
Active Locations (179)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Aabenraa, Denmark
2
Research Site
Aalborg, Denmark
3
Research Site
Albertslund, Denmark
4
Research Site
Allingåbro, Denmark